Puxin Biopharmaceutical

Puxin Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative antibody-based therapeutics for oncology. The company leverages its proprietary antibody discovery platform to engineer high-affinity monoclonal and bispecific antibodies targeting immune checkpoints and tumor-associated antigens. Puxin's pipeline is primarily focused on next-generation immunotherapy, with several candidates currently undergoing early-phase clinical trials for various solid tumors. By integrating advanced protein engineering with deep biological insights, the company aims to provide more effective treatment options for patients with refractory cancers.